Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
JAGX

JAGX - Jaguar Health Inc Stock Price, Fair Value and News

$0.68-0.02 (-2.86%)
Market Closed

64/100

JAGX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

64/100

JAGX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.96

Target 3M

$0.8

Target 6M

$0.85

JAGX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

JAGX Price Action

Last 7 days

-16.0%

Last 30 days

-34.0%

Last 90 days

-65.7%

Trailing 12 Months

-97.1%

JAGX RSI Chart

JAGX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

JAGX Valuation

Market Cap

913.5K

Price/Earnings (Trailing)

-0.02

Price/Sales (Trailing)

0.08

EV/EBITDA

0.07

Price/Free Cashflow

-0.04

JAGX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.96

Target 3M

$0.8

Target 6M

$0.85

JAGX Fundamentals

JAGX Revenue

Revenue (TTM)

11.8M

Rev. Growth (Yr)

-0.8%

Rev. Growth (Qtr)

3.49%

JAGX Earnings

Earnings (TTM)

-40.3M

Earnings Growth (Yr)

3.57%

Earnings Growth (Qtr)

8.7%

JAGX Profitability

Operating Margin

81.92%

EBT Margin

-348.22%

Return on Equity

-924.36%

Return on Assets

-81.45%

Free Cashflow Yield

-2.8K%

JAGX Investor Care

Shares Dilution (1Y)

608.69%

Diluted EPS (TTM)

-30.53

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202511.6M11.8M11.8M0
202410.0M10.2M10.5M11.7M
202311.4M10.9M10.3M9.8M
20226.2M8.1M10.1M12.0M
20210004.3M
20205.1M6.5M8.3M9.4M
20195.2M6.0M5.9M5.8M
20184.3M4.3M4.4M4.4M
2017925.8K1.8M2.8M4.4M
2016234.1K195.1K167.8K141.5K
2015000258.4K
Get all data in R, Python etc through our Historical Stock Data APIs

About Jaguar Health Inc

JAGX
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.
 CEO
 WEBSITEhttps://jaguar.health
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES60

Jaguar Health Inc Frequently Asked Questions

JAGX is the stock ticker symbol of Jaguar Health Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Jaguar Health Inc is 913.54 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check JAGX's fair value in chart for subscribers.

The fair value guage provides a quick view whether JAGX is over valued or under valued. Whether Jaguar Health Inc is cheap or expensive depends on the assumptions which impact Jaguar Health Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for JAGX.

As of Wed Jan 28 2026, JAGX's PE ratio (Price to Earnings) is -0.02 and Price to Sales (PS) ratio is 0.08. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. JAGX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Jaguar Health Inc has provided -0.848 (multiply by 100 for percentage) rate of return.